Personalis Inc.
Company Snapshot
Company Overview
Personalis Inc. develops and markets NGS-based technologies and molecular profiling platforms. Personalis operates two business segments: population sequencing services for the Department of Veterans Affairs Million Veteran Program and cancer genomics services. Personalis’ molecular profiling platform, NeXT, can provide information on as many as 20,000 human genes, giving a comprehensive overview of a patient’s immune system with a single sample. The firm provides extremely sensitive tests that use proprietary algorithms in conjunction with tumor-and-normal profiling to provide cutting-edge insights. The technologies provided are intended to improve the biomarker approach for drug development, enabling the selection of tailored treatments based on ultra-comprehensive genomic profiling and identifying minimum residual disease (MRD) and recurrence at the earliest time points.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Pharma tests and services : Pharma tests and services includes Testing Services, Data Analytics for Clinical Trials, Research to Pharmaceutical Companies in support of their drug development programs.
- Enterprise sales : Enterprise sales includes Tumor Profiling, Diagnostic Tests directly to another business as an input to their products.
- Population sequencing : Population sequencing includes Genomic Sequencing Services, Data Analytics to support Large-scale Genetic Research Programs.
- Other : Other includes Genomic Tests, Analytics to universities and non-profits. This category also includes Diagnostics Tests ordered by healthcare providers for Cancer Patients.
Applications/End User Industries
- Healthcare
- Pharmaceutical
- Drug Development
- Data Analytics
- Biopharma
- Biotechnology
- Genomic Sequencing
- Tumor Profiling
- Genetic Research
- Tumor Sequencing and Analysis
